相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Scott Kaatz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation A Meta-analysis
Shikhar Agarwal et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control
Allan C. Skanes et al.
CANADIAN JOURNAL OF CARDIOLOGY (2012)
Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno et al.
CHEST (2012)
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
Jeffrey L. Anderson et al.
CIRCULATION (2012)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
Stefan H. Hohnloser et al.
CIRCULATION (2012)
Pharmacodynamic and pharmacokinetic basics of rivaroxaban
Reinhold Kreutz
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2012)
The Use of Dabigatran Immediately After Atrial Fibrillation Ablation
Roger A. Winkle et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2012)
DABIGATRAN AND MYOCARDIAL INFARCTION, DRUG OR CLASS EFFECT. META-ANALYSIS OF RANDOMIZED TRIALS WITH ORAL DIRECT THROMBIN INHIBITORS
Ramin Artang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper
Raffaele De Caterina et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
Gregory Y. H. Lip et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation Results From a Multicenter Prospective Registry
Dhanunjaya Lakkireddy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents
Toshio Fukuda et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
Menno V. Huisman et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
Daniel E. Salazar et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study
Amitava Banerjee et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
James V. Freeman et al.
ANNALS OF INTERNAL MEDICINE (2011)
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Shimoli V. Shah et al.
CIRCULATION (2011)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
John W. Eikelboom et al.
CIRCULATION (2011)
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion
Rangadham Nagarakanti et al.
CIRCULATION (2011)
2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Update on Dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
L. Samuel Wann et al.
CIRCULATION (2011)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Edoxaban A New Oral Direct Factor Xa Inhibitor
A. John Camm et al.
DRUGS (2011)
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
Mattias Wieloch et al.
EUROPEAN HEART JOURNAL (2011)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Keith A. A. Fox et al.
EUROPEAN HEART JOURNAL (2011)
Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants
Linda M. Bavisotto et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Transforming oral anticoagulation by combining international normalized ratio (INR) self testing and online automated management
Henry I. Bussey
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
John H. Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting A North-American perspective
David P. Faxon et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe
Kurt Huber et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
Sonja V. Sorensen et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
Arlene M. Gallagher et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation A consensus document of the Italian Federation of Thrombosis Centers (FCSA)
Vittorio Pengo et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy
Gregory Y. H. Lip et al.
THROMBOSIS RESEARCH (2011)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (vol 9, pg 1157, 2010)
H. C. Diener et al.
LANCET NEUROLOGY (2011)
Edoxaban: pharmacological principles, preclinical and early-phase clinical testing
Ramon A. Partida et al.
FUTURE CARDIOLOGY (2011)
Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Isla M. Ogilvie et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation
Michael D. Ezekowitz et al.
CIRCULATION (2010)
Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
A. John Camm et al.
EUROPEAN HEART JOURNAL (2010)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
Lars Wallentin et al.
LANCET (2010)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
Hans Chnstoph Diener et al.
LANCET NEUROLOGY (2010)
Newly Identified Events in the RE-LY Trial
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of Home Testing of International Normalized Ratio on Clinical Events.
David B. Matchar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/Stenting A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]
Gregory Y. H. Lip et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Jeffrey I. Weitz et al.
THROMBOSIS AND HAEMOSTASIS (2010)
New oral anticoagulant drugs in cardiovascular disease
Ingo Ahrens et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
David J. Ellis et al.
CIRCULATION (2009)
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
Bengt I. Eriksson et al.
CLINICAL PHARMACOKINETICS (2009)
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
Gregory Y. H. Lip et al.
EUROPEAN HEART JOURNAL (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation A Systematic Review
Yi Wan et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2008)
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Robert G. Hart et al.
ANNALS OF INTERNAL MEDICINE (2007)
Antithrombotic treatment in real-life atrial fibrillation patients:: a report from the Euro Heart Survey on Atrial Fibrillation
Robby Nieuwlaat et al.
EUROPEAN HEART JOURNAL (2006)
Atrial fibrillation and stroke in the general medicare population - A 10-year perspective (1992 to 2002)
Kamakshi Lakshminarayan et al.
STROKE (2006)
Dabigatran/dabigatran etexilate -: Prevention of DVT prevention of ischemic stroke thrombin inhibitor
LA Sorbera et al.
DRUGS OF THE FUTURE (2005)
分享论文
